104,016 SELLAS Life Sciences Group, Inc. $SLS Shares Purchased by Dagco Inc.

Dagco Inc. increased its position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 8.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,336,449 shares of the company’s stock after purchasing an additional 104,016 shares during the period. SELLAS Life Sciences Group accounts for about 2.9% of Dagco Inc.’s holdings, making the stock its 11th biggest holding. Dagco Inc.’s holdings in SELLAS Life Sciences Group were worth $16,452,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Nykredit A S acquired a new position in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $27,000. GAMMA Investing LLC lifted its stake in shares of SELLAS Life Sciences Group by 293.2% in the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock valued at $27,000 after purchasing an additional 1,630 shares during the period. California State Teachers Retirement System boosted its holdings in SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares in the last quarter. Wealthfront Advisers LLC purchased a new stake in SELLAS Life Sciences Group during the first quarter worth about $48,000. Finally, Principal Financial Group Inc. purchased a new stake in SELLAS Life Sciences Group during the first quarter worth about $53,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on SLS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Trading Up 9.8%

SLS traded up $1.02 during midday trading on Tuesday, hitting $11.51. The company’s stock had a trading volume of 4,660,101 shares, compared to its average volume of 7,871,499. The firm has a market cap of $2.33 billion, a P/E ratio of -54.84 and a beta of 2.56. SELLAS Life Sciences Group, Inc. has a 52-week low of $1.39 and a 52-week high of $15.88. The firm has a 50-day moving average price of $12.45 and a two-hundred day moving average price of $9.98.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company’s research and development programs are centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack cancer cells, as well as targeted therapies for hematologic malignancies.

SELLAS’ lead product candidate is galinpepimut-S (GPS), a multi-peptide immunotherapeutic targeting Wilms’ tumor 1 (WT1), a protein expressed in multiple types of cancer.